ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates

G. Lassiter, T. Hirose, A. D’Attilio, T. Kawai

MGH Center for Transplantation Sciences, Boston, MA

Meeting: 2022 American Transplant Congress

Abstract number: 172

Keywords: Co-stimulation, Graft survival, Immunosuppression, Preclinical trails

Topic: Basic Science » Basic Science » 12 - Immunosuppression & Tolerance: Preclinical & Translational Studies

Session Information

Session Name: Immunosuppression and Tolerance: Preclinical and Translational Studies

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:20pm-6:30pm

Location: Hynes Ballroom A

*Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been associated with higher rates of acute cellular rejection (ACR) and more effective CB has been sought. Blockade of the CD154/CD40 pathway with anti-CD154 antibody (αCD154) has been shown to be more effective in inhibiting alloimmune responses than CTLA4Ig. Despite the efficacy shown in humans and animals, clinical application of αCD154 with human IgG1 Fc was abandoned due to its prothrombotic property which appears have been mediated by FcγRIIA receptor-dependent platelet activation. To address this problem, an Fc-modified αCD154 (TNX-1500), in which Fc was modified by protein engineering to decrease binding to FcγRII, has been developed. In the current study, we have evaluated TNX-1500 for its efficacy to prevent kidney allograft rejection in NHPs.

*Methods: Nine cynomolgus macaques received MHC mismatched kidney allografts with either TNX-1500 monotherapy 20mg/kg weekly (Group A) or every two weeks with daily mycophenolate mofetil (MMF) (Group B). The results were compared with our historic results with no immunosuppression (No IS, n=5) or conventional immunosuppression (Conventional IS, n=20) with tacrolimus (Tac), MMF and methylprednisolone (Pred).

*Results: Without [ketorolac] prophylaxis, no thromboembolic complication was observed in any of the nine recipients of TNX-1500. Renal allograft survival at 6 month was 80% in Group A (n=5). Histopathology at 6 months of 4/5 recipients showed no evidence of rejection (g0,i0,t0,v0,ptc0,cg0,ci0,ct0,cv0, C4d0). One recipient was lost on day 28 with ACR2b. Four recipients have so far been tested in Group B. Although one recipient developed rejection on day 36, three other recipients in this group are currently in progress with normal kidney function at days 164, 44 and 36. Renal allograft survival at four months in Conventional I.S. was 52% (p=0.33 vs. Group A) and all five recipients without I.S. rejected their kidney allografts by day 11 (p=0.0018 vs. Group A).

*Conclusions: Excellent renal allograft survival was achieved with TNX-1500 monotherapy without thromboembolic complications. The optimal dosage of TNX-1500 remains to be defined.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Lassiter G, Hirose T, D’Attilio A, Kawai T. Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-rejection-free-renal-allograft-survival-with-fc-modified-anti-cd154-antibody-monotherapy-in-nonhuman-primates/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences